Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment
A. Schwenk et al., Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment, AM J CLIN N, 72(2), 2000, pp. 496-501
Background: Highly active antiretroviral treatment (HAART) reduces the risk
of wasting in HIV infection and may alter the prognostic weight of wasting
. The phase angle from bioelectrical impedance analysis (BIA) can be interp
reted as a surrogate marker for the catabolic reaction to chronic HIV infec
tion and opportunistic disease.
Objective: Our objective was to assess the prognostic ability of the phase
angle in HIV-infected patients in the era of HAART.
Design: Two cross-sectional observation studies were conducted in 1996 and
1997 at a German university outpatient HIV clinic. In the 1996 and 1997 coh
orts, HAART was prescribed to 17 of 212 and 168 of 257 patients at baseline
and to 179 of 212 and 234 of 257 patients during observation, respectively
. Whole-body BIA was assessed at 50 KHz. Time to clinical progression and s
urvival were calculated by using Cox proportional. hazard models with time-
dependent covariates. Median observation times were 1000 and 515 d for the
1996 and 1997 cohorts, respectively.
Results: Higher phase angle was associated with a lower relative mortality
risk, adjusted for viral load and CD4(+) cell count, of 0.49 (95% CI: 0.30,
0.81) per degree in 1996 and of 0.33 (95% CI: 0.18, 0.61) in 1997. The inf
luence of phase angle on time to clinical progression, adjusted for viral l
oad and CD4(+) cell count, was not significant in 1996 but the relative ris
k was 0.58 (0.36, 0.83) in 1997.
Conclusion: Despite the favorable effects of HAART on the nutritional statu
s of HIV-infected persons, low phase angle remains an independent adverse p
rognostic marker of clinical progression and survival.